BioCentury
ARTICLE | Company News

InSite, Bausch & Lomb deal

January 5, 2004 8:00 AM UTC

ISV sold to BOL its ISV-403 to treat ocular bacterial infections. ISV received a cash payment and reimbursement for product development expenses, and is eligible for royalties. The sale cancels the c...